We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2331:TSEALSOK CO., LTD. Analysis

Data as of 2026-05-18 - not real-time

HK$18.49

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Li Ning (2331.HK) is trading at HK$18.49, well below its 20‑day (≈19.88) and 200‑day (≈19.04) simple moving averages, indicating a price lag despite a relatively low 31.9 RSI that suggests the stock is oversold. Technical momentum remains bearish as the MACD line sits beneath its signal (‑0.57 vs ‑0.45) and volume is trending downward, yet the proximity to the identified support level of HK$18.05 offers a potential floor. Valuation metrics reinforce the upside case: the DCF‑derived fair value of roughly HK$22.0 and analyst consensus targets around HK$25.5 imply a 40%‑plus upside, while the current PE of 14.1 and forward PE of 11.9 are modest for a consumer‑cyclical brand.
Fundamentally, Li Ning boasts a strong balance sheet with HK$17.8 bn cash versus HK$2.1 bn debt (debt‑to‑equity ~7%), healthy gross margins near 49% and a ROE of 11%, supporting its ability to sustain a generous 3.4% dividend yield. The payout ratio of 77% is high but backed by solid free cash flow (≈HK$2.7 bn) and a low beta of 0.35, indicating limited market‑wide volatility despite a 30‑day price volatility of over 30%. Analyst sentiment is bullish (median recommendation “Buy”), and the Fear & Greed index at 89.6 reflects extreme market optimism, further underscoring the potential for price recovery.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Oversold RSI and price near support
  • High dividend yield providing immediate income
  • Potential bounce supported by low beta

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation upside to DCF fair value
  • Strong cash position and low leverage
  • Analyst consensus of Buy with favorable earnings outlook

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Brand positioning in China’s growing sports market
  • Sustainable dividend policy backed by cash flow
  • Undervalued relative to peers with modest earnings growth

Key Metrics & Analysis

Financial Health

Revenue Growth3.10%
Profit Margin9.92%
P/E Ratio14.1
ROE10.93%
ROA7.01%
Debt/Equity7.44
P/B Ratio1.5
Op. Cash FlowHK$4.9B
Free Cash FlowHK$2.7B

Technical Analysis

TrendNeutral
RSI31.9
SupportHK$18.05
ResistanceHK$21.80
MA 20HK$19.88
MA 50HK$20.56
MA 200HK$19.04
MACDBearish
VolumeDecreasing
Fear & Greed Index89.61

Valuation

Fair ValueHK$21.98
Target PriceHK$25.89
Upside/Downside40.03%
GradeUndervalued
TypeBlend
Dividend Yield3.39%

Risk Assessment

Beta0.35
Volatility32.86%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.